Heterocyclic Compounds

Matches 451 - 500 out of 53,986	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >

Document	Document Title
WO/2023/239941A1	IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed ...
WO/2023/239945A1	BTOLOGICAL ACTIVITIES OF 5-(2-(4-(4-FLUORO-2-METHYL-1H-INDOL-5- YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)ETHYL)-5-AZASPIRO[2.4]-HEPTAN- 7-OL CRYSTALLINE, PHOSPHORIC ACID SALT AND ITS ENANTIOMERS Disclosed herein relates to the biological activities and preparation of 5-(2-(4-(4-fluoro-2- methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5- azaspiro[2.4]-heptan-7-ol (Compound A) stable crystalline form (Compound A-Xln); i...
WO/2023/237055A1	USE OF CDK4/6 INHIBITOR IN TREATMENT OF DEDIFFERENTIATED LIPOSARCOMA The present disclosure belongs to the technical field of medicines, and relates to the use of a CDK4/6 inhibitor in treatment of dedifferentiated liposarcoma, in particular to the use of a compound of formula (I) in treatment of dediffer...
WO/2023/238112A1	SOLID STATE FORMS OF PALTUSOTINE AND PROCESS FOR PREPARATION THEREOF The present disclosure encompasses solid state forms of Paltusotine, in embodiments crystalline polymorphs of Paltusotine or salts of Paltusotine, particularly Paltusotine monomesylate and Paltusotine hemimesylate, processes for preparat...
WO/2023/236820A1	AROMATIC SIX-MEMBERED RING-FUSED IMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF An aromatic six-membered ring-fused imidazole derivative, and a preparation method therefor and the use thereof, which belongs to the field of drug synthesis. Specifically, the present invention relates to an aromatic six-membered ring-f...
WO/2023/239750A1	BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail....
WO/2023/239729A1	PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable s...
WO/2023/239634A2	INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM The present invention is directed to novel organic compounds demonstrating the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems. The novel compounds include zwitterion moieties...
WO/2023/236947A1	SUBSTITUTED PYRIDAZINE-3-CARBOXAMIDE COMPOUND SERVING AS TYK2 INHIBITOR The present invention provides a pyridazine-3-carboxamide compound of general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof. The p...
WO/2023/237049A1	DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE Disclosed herein are novel bifunctional compounds formed by conjugating IRAK4 inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparati...
WO/2023/240205A1	DEUTERATED COMPOUNDS The present disclosure provides deuterated compounds and their use as T-type calcium channel blockers in the treatment or prevention of various diseases or disorders associated with calcium T channels.
WO/2023/237116A1	PROTEIN DEGRADERS AND USES THEREOF The present invention discloses a protein degrader such as a GSPT1 degrader and use thereof, particularly use in the prevention and/or treatment of diseases.
WO/2023/239846A1	HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS The present application provides heterocyclic compounds of formula (I) that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.
WO/2023/231795A1	HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME The present invention relates to the technical field of organic electroluminescent materials, and particularly relates to a heterocyclic compound and the use thereof. The structural formula of the compound is as shown in formula (I). The...
WO/2023/235305A2	SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF The invention provides novel sulfonyl cyclic derivatives, and compositions and methods of preparation and use thereof, that are useful in treating various diseases and disorders related to TRPML activities such as lysosome storage diseas...
WO/2023/232917A1	NOVEL COMPOUNDS The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2023/232674A1	HERBICIDAL DERIVATIVES Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
WO/2023/232133A1	COMPOUND FOR INHIBITING OR DEGRADING BCL6 AND USE THEREOF IN PHARMACEUTICS The present invention relates to a compound represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or an eutectic thereof, and an intermediate and a...
WO/2023/235535A1	FLUORESCENTLY-ACTIVE FREE RADICAL TAGS FOR SIMULTANEOUS GLYCAN QUANTITATION AND CHARACTERIZATION Provided are compounds useful for the quantitation and/or characterization of glycans and other similar molecules. Such compounds include compounds of formula (la) or (lb) substituted with at least a TEMPO group or analog thereof and a c...
WO/2023/233024A1	DPP9 BINDING COMPOUNDS The invention relates to new compounds of the general Formula (I), which are Dipeptidyl peptidase 9 (DPP9) enzyme inhibitors. The present invention further relates to specific compounds based on Formula (I) that binds to an E3 ligase and...
WO/2023/231997A1	PYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided in the present invention are a pyridazine compound represented by formula (II), and a preparation method therefor and the use thereof. Further disclosed in the present invention is the use of the compound of the present inventio...
WO/2023/232673A1	HERBICIDAL DERIVATIVES Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
WO/2023/230968A1	SHP2 INHIBITOR, AND CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are an SHP2 inhibitor, and a crystal form thereof, a preparation method therefor, and a use thereof. Provided are a crystal form B of a compound as shown in formula (I), a compound as shown in formula (II) and a crystal form A t...
WO/2023/235880A1	CD38 MODULATORS AND USES THEREOF The disclosure provides compounds of Formula (I) and salts thereof for use in medical treatment.
WO/2023/234749A1	COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
WO/2023/235618A1	FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical composit...
WO/2023/232069A1	AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF An azaquinolinone compound having a structure of the following formula (I) as an enzyme inhibitor for the poly(ADP-ribose)polymerase (PARP) family, and a pharmaceutically acceptable salt, a stereoisomer, a tautomer or an N-oxide drug the...
WO/2023/232130A1	HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF Disclosed in the present invention are a heterocyclic compound as shown in formula (I) or a stereoisomer, deuterated compound, solvate, pharmaceutically acceptable salt, or co-crystal thereof and a pharmaceutical composition thereof, and...
WO/2023/235384A1	COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termina...
WO/2023/234425A1	AMINO ACID ACTIVE ESTER AND SALT THEREOF The present invention provides a novel active ester of an amino acid to be used for amino acylation of tRNA, said ester being capable of reducing risks to safety and waste. The present invention provides a compound represented by formula...
WO/2023/226679A1	3C-LIKE PROTEASE INHIBITOR The present invention provides a 3C-like protease inhibitor represented by formula (I), or a pharmaceutically acceptable salt or ester thereof, and a stereoisomer or tautomer, a racemate, a nitrogen oxide, a polymorph, a hydrate, a solva...
WO/2023/230205A1	MEK INHIBITORS AND USES THEREOF The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.
WO/2023/230609A1	HETEROCYCLIC PAD4 INHIBITORS The disclosure generally relates to compounds of Formula I, comprising a 1,6,7,8-tetrahydro-5H-imidazo[4,5-g][1,6]isoquinolin-5-one moiety directly bonded to an azaindole or indole moiety, such compounds as inhibitors of PAD4, methods fo...
WO/2023/230480A2	COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF HIV Compositions and methods for treating HIV using compounds that sensitize HIV‐1 infected cells to antibody-dependent cellular cytotoxicity.
WO/2023/229430A1	HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF The present invention relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent fo...
WO/2023/229322A1	METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVES The present invention relates to a method for preparing 6-methoxypyridin-3-yl derivatives. The preparation method according to the present invention has the advantage of allowing the reaction to be conducted under mild conditions that en...
WO/2023/227125A1	NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF Disclosed in the present invention is a new fused-heterocyclic compound having target inhibitory activity for CDKs, and specifically disclosed is a compound having a structure as represented by formula (I) as a target inhibitor for CDKs ...
WO/2023/229323A1	METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVE The present invention relates to a method for preparing a 6-methoxypyridin-3-yl derivative. The preparation method according to the present invention has an advantage in that the reaction can be carried out under mild conditions which en...
WO/2023/227080A1	PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a PROTAC compound, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. The PROTAC compound has a structure as represented by formula (I), and can be used for treating BTK-rela...
WO/2023/227117A1	3C-LIKE PROTEASE INHIBITOR Provided in the present invention is a 3C-like protease inhibitor as shown in formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof. Also provided in ...
WO/2023/226965A1	ROCK INHIBITORS AND USES THEREOF Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as ROCK inhibitors. Also disclosed are pharmaceutical compositions comprising a compound of Formula (I), and methods of using s...
WO/2023/229375A1	HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF The present invention relates to a heterocyclic compound represented by chemical formula 1, exhibiting a diacylglycerol kinase inhibitor activity, a pharmaceutical composition comprising same as an active ingredient, and use thereof.
WO/2023/230477A1	PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a. subject in need a. therapeutically effective amount of a Chk1 inhibitor disclosed herein.
WO/2023/227946A1	TYK2 INHIBITORS AND USES THEREOF Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
WO/2023/227052A1	BICYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF Disclosed herein are a compound represented by formula (II) or a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated form thereof, or a pharmaceutical composition comprising same, and use thereof as ...
WO/2023/226323A1	QUINAZOLINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to the technical field of chemical medicine, and in particular to a quinazoline derivative, and a preparation method therefor and the use thereof. The quinazoline derivative provided by the present invention...
WO/2023/220831A1	HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kina...
WO/2023/222115A1	HYDROXYAMIDE DERIVATIVE AND USE THEREOF Provided in the present application is a hydroxyamide derivative represented by formula (I), and a tautomer, stereoisomer, solvate, metabolite, isotopically-labeled compound, pharmaceutically acceptable salt or co-crystal thereof. The co...
WO/2023/225588A2	NOVEL ISOQUINOLONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE Aspects of this invention are related to novel compounds of Formula I and compositions thereof that are inhibitors of glycogen synthase kinase 3 beta (GSK3[3). Some aspects of the invention relate to novel compounds and compositions havi...
WO/2023/224853A1	AT2R ANTAGONISTS AND USES THEREOF This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof,...

Matches 451 - 500 out of 53,986	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >